Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexaxim immunogenicity and safety in HIV-exposed infants in South Africa
2018-004708-21Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2019
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of hexaxim in vaccine-preventable bacterial and viral infections (VPD) (2 arms), sponsored by Sanofi. Primary endpoints: Anti-pertussis toxoid and anti-filamentous hemagglutinin antibody response and Post-primary series immunogenicity.
02
Drugs
hexaxim
03
Conditions
vaccine-preventable bacterial and viral infections (VPD)
Beyond the preview
Go deeper on 2018-004708-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004708-21.